{"id":"NCT01474512","sponsor":"Eli Lilly and Company","briefTitle":"A Phase 3 Study in Participants With Moderate to Severe Psoriasis","officialTitle":"A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11-16","primaryCompletion":"2014-06-24","completion":"2018-09-20","firstPosted":"2011-11-18","resultsPosted":"2016-05-27","lastUpdate":"2019-10-03"},"enrollment":1296,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"80 mg Ixekizumab Dosing Regimens 1, 2, and 3","otherNames":["LY2439821"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W)","type":"EXPERIMENTAL"},{"label":"80 mg Ixekizumab Dosing Regimen 2 (Q4W)","type":"EXPERIMENTAL"},{"label":"80 mg Ixekizumab Dosing Regimen 3 (Q12W)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the safety and efficacy of LY2439821 compared to placebo in participants with moderate to severe, chronic plaque psoriasis.","primaryOutcome":{"measure":"Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo","deltaMin":3.2,"sd":null},{"arm":"Ixe Q4W","deltaMin":76.4,"sd":null},{"arm":"Ixe Q2W","deltaMin":81.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":104,"countries":["United States","Australia","Canada","Denmark","Germany","Hungary","Italy","Japan","Poland","Romania","United Kingdom"]},"refs":{"pmids":["38647975","37400681","35279805","32200512","27299809","26953848"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":431},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Injection site reaction","Arthralgia","Headache"]}}